Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) SEC filings, changes and red flags

Red flags

No red flags have been raised by Regeneron Pharmaceuticals, Inc.’s filings on file.

Filings

Form Period Filed What it reports Flags
8-K Oct 1, 2026 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 8.01 Other events
8-K Sep 24, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 9 added · 4 removed · 24 modified
P2I1A: no comparison — low extraction confidence
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 2.02 Results of operations and financial condition
8-K Jun 12, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 8, 2026 2.02 Results of operations and financial condition
10-K Dec 31, 2025 1: 27 added · 19 removed · 108 modified
1A: 16 added · 10 removed · 141 modified
7: 14 added · 17 removed · 29 modified
8-K Jan 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2025 2.02 Results of operations and financial condition
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.